Shenzhen based Xige Biotech announced the first close of a Series A plus round worth several hundred million renminbi on 4 November 2026. China Life Equity led the financing. Xige develops drug candidates using patient derived organoid models and artificial intelligence to study disease biology and identify targets. The company is advancing programmes in metastatic solid tumours while expanding into cardiac and kidney disease. The capital will support clinical development, new pipelines and further work on its research platform. Two independent Chinese technology and investment publications reported the financing, while a direct company announcement was not located.
Xige Biotech closes Series A plus first tranche
China Life Equity backs organoid based drug development

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


